CLINICAL TRIALS PROFILE FOR TERBINAFINE
✉ Email this page to a colleague
All Clinical Trials for Terbinafine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00117754 ↗ | Terbinafine Compared to Griseofulvin in Children With Tinea Capitis | Completed | Novartis | Phase 3 | 2004-07-01 | Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis. |
| NCT00117767 ↗ | Terbinafine Compared to Griseofulvin in Children With Tinea Capitis | Completed | Novartis Pharmaceuticals | Phase 3 | 2004-06-01 | Tinea capitis is a dermatophyte infection of the scalp hair follicles, which occurs primarily in children. Hair loss, hair breakage, scaling, plus various degrees of erythema, pustules and pruritus are the primary clinical signs which can be associated with tinea capitis. The infection is caused by a relatively small group of dermatophytes in the genera Trichophyton and Microsporum. Terbinafine hydrochloride is a synthetic allylamine derivative antifungal agent. This study will evaluate the efficacy and safety of terbinafine in children with tinea capitis. |
| NCT00253305 ↗ | Topical Gel Anti-Fungal Agent for Tinea Unguium | Completed | MediQuest Therapeutics | Phase 2 | 2005-09-01 | The purpose of this study is to compare, in a controlled fashion, the response to two anti-fungal agents, naftifine or terbinafine, with vehicle in novel topical gel formulations in the treatment of subjects with distal subungual tinea unguium of the toenails (onychomycosis). The formulation used as the vehicle for the active agents has been shown in earlier studies to facilitate the penetration of the active agent through fungally-infected nails. This study will examine dose-response and agent differences in terms of efficacy and safety. Once the subject has qualified for the study, he/she will be randomly assigned to one of five study groups, dispensed appropriate study medication and instructed to apply one drop to the great toe designated for study. |
| NCT00386802 ↗ | Antifungal Use in Oncohematological Neutropenic Patients | Completed | PETHEMA Foundation | Phase 4 | 2006-08-01 | Primary purpose: Frequency of use of broad-spectrum antifungals in the episode of neutropenia. Secondary purposes:To determine the safety and toxicity measure by: 1. Frequency of Invader Fungal Infection. 2. Frequency of global use of broad-spectrum antifungals as amphotericine, itraconazole, voriconazole, caspofungin, terbinafine, during the period of study. 3. Mortality 4. Development of nephrotoxicity 5. Use of galactomannan in this clinical context 6. Time of administration of empirical antifungal therapy of broad-spectrum. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Terbinafine
Condition Name
Clinical Trial Locations for Terbinafine
Trials by Country
Clinical Trial Progress for Terbinafine
Clinical Trial Phase
Clinical Trial Sponsors for Terbinafine
Sponsor Name
